Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa 6-hour IV infusion study of CXL-1427 in hospitalized patients with systolic heart failure
2014-000771-24Phase 2Completed
- Sponsor
- Cardioxyl Pharmaceuticals
- Start
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of cimlanod in heart failure with reduced ejection fraction (HFrEF) and Left Heart Failure, sponsored by Cardioxyl Pharmaceuticals. Primary endpoint: Safety and tolerability of CXL-1427. Started Jun 2014; status: completed.
02
Drugs
cimlanod
03
Conditions
heart failure with reduced ejection fraction (HFrEF)Left Heart Failure
Beyond the preview
Go deeper on 2014-000771-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000771-24.